Sumatriptan-naproxen for acute treatment of migraine: A randomized trial

JAMA

Volumn 297, Issue 13, 2007, Pages 1443-1454

  Brandes, Jan Lewis ^a   Kudrow, David ^b   Stark, Stuart R ^c   O'Carroll, C Phillip ^d   Adelman, James U ^e   O'Donnell, Francis J ^f   Alexander, W James ^g   Spruill, Susan E ^g   Barrett, Pamela S ^h   Lener, Shelly E ^h  

^a Nashville Neuroscience Group   (United States)

^b California Medical Clinic for Headache   (United States)

^c Innovative Clinical Research Center   (United States)

^d The Headache Institute   (United States)

^e Headache Wellness Center   (United States)

^f OrthoNeuro   (United States)

^g POZEN Inc   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; SUMATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; XEROSTOMIA; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; TABLET;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAPROXEN; SUMATRIPTAN; TABLETS; VASOCONSTRICTOR AGENTS;

EID: 34047196012     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.13.1443     Document Type: Article

References (39)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41:646-657.
2. Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med. 2005;118(suppl 1):3S-10S.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270.
4. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
5. Gendolla A. Part I: what do patients really need and want from migraine treatment? Curr Med Res Opin. 2005;21(suppl 3):S3-S7.
6. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(suppl 1):3-9.
7. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999;26:S12-S19.
8. Goadsby PJ. Current concepts of the pathophysiology of migraine. Neurol Clin. 1997;15:27-42.
9. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med. 1993; 44:145-154.
10. Watkins LR, Milligan ED, Maiser SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol. 2003; 521:1-21.
11. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89:107-110.
12. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624.
13. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123:1703-1709.
14. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27-36.
15. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55: 19-26.
16. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. 2003 Wolff Award: possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache. 2003;43:704-714.
17. Burstein R, Jakubowski M. Implications of multimechanism therapy: when to treat? Neurology. 2005; 64(suppl 2):S16-S20.
18. Burstein R, Jakubowski M, Levy D. Naproxen suppresses sensitization in of central trigeminovascular neurons - implication for migraine therapy [abstract]. Neurology. 2006;66(suppl 2):A69.
19. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58:428-430.
20. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983-991.
21. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 2004;4:10.
22. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs rizatriptan for the acute treatment of migraine: an open-label pilot study. Cephalalgia. 2002;22:309-312.
23. Naprosyn Complete Prescribing Information. Nutley, NJ: Roche Laboratories Inc; January 2006.
24. Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
25. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
26. Holm S. A simple sequentially rejective Bonferroni test procedure. Scand J Stat. 1979;6:65-70.
27. Shaffer JP. Modified sequentially rejective multiple test procedures. J Am Stat Assoc. 1986;81:826-831.
28. Holland BS, Copenhaver MD. An improved sequentially rejective Bonferroni test procedure. Biometrics. 1987;43:417-424.
29. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York, NY: John Wiley & Sons Inc; 1987.
30. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing Biometrika. 1988;75:800-803.
31. Kori S, Littlefield D, Taylor D, et al. Pharmacokinetics of a single-tablet formulation of sumatriptan RT Technology™ and naproxen sodium [abstract]. Cephalalgia. 2005;25:933.
32. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:850-861.
33. Cipolla G, Sacco S, Crema F, et al. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res. 2001;43:205-210.
34. Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther. 1992;6:685-691.
35. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache. 1992;32:280-282.
36. Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia. 1985;5:107-113.
37. Carpay J, Schoenen J, Ahmad F, et al. Efficacy and tolerability of sumatriptan tablets in a fastdisintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004; 26:214-223.
38. Sheftell FD, Dahlöf CG, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of headache relief in the acute treatment of migraine with a fast-disintegrating/rapidrelease formulation of sumatriptan tablets. Clin Ther. 2005;27:407-417.
39. Winner P, Cady RK, Ruoff GE, et al. Twelvemonth tolerability and safety of sumatriptan and naproxen sodium for the treatment of acute migraine. Mayo Clin Proc. 2007;82:61-68.